Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada.
Ingram School of Nursing, McGill University, Montreal, Quebec, Canada.
Psychooncology. 2020 Apr;29(4):788-795. doi: 10.1002/pon.5350. Epub 2020 Feb 16.
Fear of cancer recurrence (FCR) is characterized by the fear, worry or concern that cancer will come back or progress. The negative effects associated with FCR are consistently identified by cancer survivors as one of their most prominent unmet needs. Current measures of FCR can be long, complex and burdensome for survivors to complete. The objective of the present study is to develop and validate a one-item measure of FCR.
The ability of the FCR-1 to detect change in FCR over time was analyzed using a repeated-measures ANOVA and paired-samples t-tests. Pearson correlations were used to measure the concurrent, convergent and discriminant validity of the FCR-1, and a ROC analysis was conducted to determine an optimal clinical cut-off score.
The FCR-1 was found to be responsive to change in FCR over time. It demonstrated concurrent validity with the FCRI (r = .395, P = .010), and convergent validity with the Mishel Uncertainty in Illness Scale (r = .493, P = .001) and the Reassurance Questionnaire (r = .325, P = .044). Discriminant validity was confirmed when the FCR-1 did not significantly correlate with unrelated measures. A ROC analysis pinpointed an optimal clinical cut-off score of 45.0.
The FCR-1 is a promising tool that can be incorporated in clinical and research settings. Due to its brevity, the care needs of highly distressed patients can be met quickly and efficiently. In research settings, the FCR-1 can reduce the cognitive burden experienced by survivors.
对癌症复发的恐惧（Fear of cancer recurrence，FCR）的特征为对癌症复发或进展的恐惧、担忧或关注。癌症幸存者一致认为，与 FCR 相关的负面影响是他们最突出的未满足需求之一。目前用于评估 FCR 的方法可能冗长、复杂，且对幸存者来说完成负担过重。本研究的目的是开发和验证一种用于评估 FCR 的单项目测量工具。
采用重复测量方差分析和配对样本 t 检验分析 FCR-1 检测 FCR 随时间变化的能力。使用 Pearson 相关系数来衡量 FCR-1 的同时效度、收敛效度和判别效度，并进行 ROC 分析以确定最佳的临床截断分数。
FCR-1 被发现能灵敏地检测 FCR 随时间的变化。它与 FCRI（r =.395，P =.010）具有同时效度，与 Mishel 疾病不确定感量表（r =.493，P =.001）和 Reassurance Questionnaire（r =.325，P =.044）具有收敛效度。当 FCR-1 与不相关的测量指标无显著相关性时，确认了判别效度。ROC 分析确定了 45.0 的最佳临床截断分数。
FCR-1 是一种很有前途的工具，可以在临床和研究环境中使用。由于其简洁性，可以快速有效地满足高度困扰的患者的护理需求。在研究环境中，FCR-1 可以减轻幸存者的认知负担。
